Endogenous sex hormones and prostate cancer: a quantitative review of prospective studies

Abstract

This paper presents a quantitative review of the data from eight prospective epidemiological studies, comparing mean serum concentrations of sex hormones in men who subsequently developed prostate cancer with those in men who remained cancer free. The hormones reviewed have been postulated to be involved in the aetiology of prostate cancer: androgens and their metabolites testosterone (T), non-SHBG-bound testosterone (non-SHBG-bound T), di-hydrotestosterone (DHT), androstanediol glucuronide (A-diol-g), androstenedione (A-dione), dehydroepiandrosterone sulphate (DHEAS), sex hormone binding globulin (SHBG), the oestrogens, oestrone and oestradiol, luteinizing hormone (LH) and prolactin. The ratio of the mean hormone concentration in prostate cancer cases to that of controls (and its 95% confidence interval (CI)) was calculated for each study, and the results summarized by calculating the weighted average of the log ratios. No differences in the average concentrations of the hormones were found between prostate cancer cases and controls, with the possible exception of A-diol-g which exhibited a 5% higher mean serum concentration among cases relative to controls (ratio 1.05, 95% CI 1.00-1.11), based on 644 cases and 1048 controls. These data suggest that there are no large differences in circulating hormones between men who subsequently go on to develop prostate cancer and those who remain free of the disease. Further research is needed to substantiate the small difference found in A-diol-g concentrations between prostate cancer cases and controls.

References 24

1. 1.

   Adlercreutz H. Western diet and Western diseases: some hormonal and biochemical mechanisms and associations. Scand J Clin Lab Invest Suppl. 1990;201:3-23.

   Not in our library

2. 2.

   Barrett-Connor E., Garland C., McPhillips J. B., Khaw K. T., Wingard D. L. A prospective, population-based study of androstenedione, estrogens, and prostatic cancer. Cancer Res. 1990;50(1):169-173.

   Not in our library

3. 3.

   Breslow N., Chan C. W., Dhom G., Drury R. A., Franks L. M., Gellei B., Lee Y. S., Lundberg S., Sparke B., Sternby N. H. Latent carcinoma of prostate at autopsy in seven areas. The International Agency for Research on Cancer, Lyons, France. Int J Cancer. 1977;20(5):680-688.

   Not in our library10.1002/ijc.2910200506 (opens in a new tab)

4. 4.

   Carter H. B., Pearson J. D., Metter E. J., Chan D. W., Andres R., Fozard J. L., Rosner W., Walsh P. C. Longitudinal evaluation of serum androgen levels in men with and without prostate cancer. Prostate. 1995;27(1):25-31.

   Not in our library10.1002/pros.2990270106 (opens in a new tab)

5. 5.

   Comstock G. W., Gordon G. B., Hsing A. W. The relationship of serum dehydroepiandrosterone and its sulfate to subsequent cancer of the prostate. Cancer Epidemiol Biomarkers Prev. 1993;2(3):219-221.

   Not in our library

6. 6.

   Devgan S. A., Henderson B. E., Yu M. C., Shi C. Y., Pike M. C., Ross R. K., Reichardt J. K. Genetic variation of 3 beta-hydroxysteroid dehydrogenase type II in three racial/ethnic groups: implications for prostate cancer risk. Prostate. 1997;33(1):9-12.

   Not in our library10.1002/(sici)1097-0045(19970915)33:1<9::aid-pros2>3.0.co;2-h (opens in a new tab)

7. 7.

   Dorgan J. F., Albanes D., Virtamo J., Heinonen O. P., Chandler D. W., Galmarini M., McShane L. M., Barrett M. J., Tangrea J., Taylor P. R. Relationships of serum androgens and estrogens to prostate cancer risk: results from a prospective study in Finland. Cancer Epidemiol Biomarkers Prev. 1998;7(12):1069-1074.

   Not in our library

8. 8.

   Flanders W. D. Case-control studies of selected hormones and prostate cancer. An epidemiologic review. Ala J Med Sci. 1986;23(4):439-443.

   Not in our library

9. 9.

   Gann P. H., Hennekens C. H., Ma J., Longcope C., Stampfer M. J. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst. 1996;88(16):1118-1126.

   Not in our library10.1093/jnci/88.16.1118 (opens in a new tab)

10. 10.

    Guess H. A., Friedman G. D., Sadler M. C., Stanczyk F. Z., Vogelman J. H., Imperato-McGinley J., Lobo R. A., Orentreich N. 5 alpha-reductase activity and prostate cancer: a case-control study using stored sera. Cancer Epidemiol Biomarkers Prev. 1997;6(1):21-24.

    Not in our library

11. 11.
    The early in utero oestrogen and testosterone environment of blacks and whites: potential effects on male offspring · 1988

    No notice
12. 12.

    Hsing A. W., Comstock G. W. Serological precursors of cancer: serum hormones and risk of subsequent prostate cancer. Cancer Epidemiol Biomarkers Prev. 1993;2(1):27-32.

    Not in our library

13. 13.

    Montie J. E., Pienta K. J. Review of the role of androgenic hormones in the epidemiology of benign prostatic hyperplasia and prostate cancer. Urology. 1994;43(6):892-899.

    Not in our library10.1016/0090-4295(94)90163-5 (opens in a new tab)

14. 14.

    Nomura A. M., Kolonel L. N. Prostate cancer: a current perspective. Epidemiol Rev. 1991;13:200-227.

    Not in our library10.1093/oxfordjournals.epirev.a036069 (opens in a new tab)

15. 15.

    Nomura A. M., Stemmermann G. N., Chyou P. H., Henderson B. E., Stanczyk F. Z. Serum androgens and prostate cancer. Cancer Epidemiol Biomarkers Prev. 1996;5(8):621-625.

    Not in our library

16. 16.

    Nomura A., Heilbrun L. K., Stemmermann G. N., Judd H. L. Prediagnostic serum hormones and the risk of prostate cancer. Cancer Res. 1988;48(12):3515-3517.

    Not in our library

17. 17.

    Parker S. L., Tong T., Bolden S., Wingo P. A. Cancer statistics, 1996. CA Cancer J Clin. 1996;46(1):5-27.

    Not in our library10.3322/canjclin.46.1.5 (opens in a new tab)

18. 18.

    Reichardt J. K., Makridakis N., Henderson B. E., Yu M. C., Pike M. C., Ross R. K. Genetic variability of the human SRD5A2 gene: implications for prostate cancer risk. Cancer Res. 1995;55(18):3973-3975.

    Not in our library

19. 19.

    Ross R. K., Bernstein L., Lobo R. A., Shimizu H., Stanczyk F. Z., Pike M. C., Henderson B. E. 5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet. 1992;339(8798):887-889.

    Not in our library10.1016/0140-6736(92)90927-u (opens in a new tab)

20. 20.

    Ross R., Bernstein L., Judd H., Hanisch R., Pike M., Henderson B. Serum testosterone levels in healthy young black and white men. J Natl Cancer Inst. 1986;76(1):45-48.

    Not in our library

21. 21.
    Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County · 1991

    No notice
22. 22.

    Thomas H. V., Reeves G. K., Key T. J. Endogenous estrogen and postmenopausal breast cancer: a quantitative review. Cancer Causes Control. 1997;8(6):922-928.

    Not in our library10.1023/a:1018476631561 (opens in a new tab)

23. 23.

    Vatten L. J., Ursin G., Ross R. K., Stanczyk F. Z., Lobo R. A., Harvei S., Jellum E. Androgens in serum and the risk of prostate cancer: a nested case-control study from the Janus serum bank in Norway. Cancer Epidemiol Biomarkers Prev. 1997;6(11):967-969.

    Not in our library

24. 24.

    Vermeulen A., Verdonck G. Representativeness of a single point plasma testosterone level for the long term hormonal milieu in men. J Clin Endocrinol Metab. 1992;74(4):939-942.

    Not in our library10.1210/jcem.74.4.1548361 (opens in a new tab)

Questions about this paper

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.